Plandai Products Offer Aid for Summertime Skin Ailments

Marketwired

BALTIMORE, MD--(Marketwired - Jun 28, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Plandai Biotechnology Inc. (OTCQB: PLPL) may offer products that can be adapted to treat various skin ailments and conditions caused by excessive time in the sun. Plandai is a developer of highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

For example, Plandai's Phytofare™ Catechin Complex is derived from Green Tea that could prove to be used to target the large anti-aging market. Studies have demonstrated that catechins found in green tea, such as EGCG (Epigallocatechin Gallate), are powerful antioxidants that can support a healthier immune system and be used as a treatment for multitude of conditions, including sunburn, and even help rejuvenate skin cells.

To that end, Plandai has spent over a decade developing its Phytofare™ Catechin Complex, which is processed to deliver a natural, antioxidant-rich product that contains the full range of green tea catechins at a bioavailability level many times that of other products available on the market. They are currently testing a nano-encapsulated version of the Phytofare™ product in a topical application specifically to assess depth of penetration in anticipation of reaching out to anti-aging product manufacturers. The Company's Phytofare™ Nutricare product line is slated for launch in the fourth quarter of 2013 and as additional applications for its products are discovered and developed, Plandai's product flexibility superiority will no doubt drive its revenue and earnings growth.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com

Rates

View Comments (0)